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Background: The aim of this study was to evaluate the effects of increasing doses of inhaled histamine on the
forced expiratory volume in one second (FEV1), inspiratory lung function parameters (ILPs) and dyspnea in subjects
with mild to moderate chronic obstructive pulmonary disease (COPD).
Methods: Thirty-nine (27 males and 12 females) stable COPD patients (GOLD stages I and II) inhaled a maximum of
six sequential doses of histamine according to ERS standards until one of these provocative doses produced a 20%
decrease in FEV1 (PD20). The effects on the FEV1, the forced inspiratory volume in one second (FIV1), inspiratory
capacity (IC), forced inspiratory flow at 50% of the vital capacity (FIF50), peak inspiratory flow (PIF) and dyspnea
score by a visual analogue scale (VAS) were measured and investigated after each dose step.
Results: After each dose of histamine, declines in all of the lung function parameters were detected; the largest
decrease was observed in the FEV1. At the PD20 endpoint, more FEV1 responders than ILP responders were found.
Among the ILPs, the FIV1 and IC best predicted which patients would reach the PD20 endpoint. No significant
correlations were found between any of the lung function parameters and the VAS results.
Conclusions: In COPD patients, the FEV1 and ILPs declined after each dose of inhaled histamine. FEV1 was more
sensitive to histamine than the ILPs. Of the ILPs, FIV1 and IC were the best predictors of reaching the PD20
endpoint. No statistically significant correlations were found between the lung function parameters and the degree
of dyspnea.
Keywords: Chronic obstructive pulmonary disease, Forced expiratory volume 1 second, Inspiratory lung functions
parameters, Visual analogue scaleBackground
Bronchial hyper-responsiveness (BHR) is defined as
increased airway sensitivity to various inhaled pharmaco-
logical agents (e.g., histamine or methacholine) and
physiological stimuli (e.g., cold air or hypotonic salt)
resulting in narrowing of the bronchi. A BHR test is con-
sidered to be positive when a provocative concentration of
less than 8 mg/ml of histamine or methacholine (PC20) or
a provocative dose (PD20) of less than 7.8 μmol of these* Correspondence: SRamlal@ysl.nl
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reproduction in any medium, provided the origbronchoconstrictive agents causes a ≥20% decrease from
the baseline value of the forced expiratory volume in one
second (FEV1) [1]. There is an approximately 50% BHR
prevalence rate in subjects with mild chronic obstructive
pulmonary disease (COPD), and BHR is more prevalent in
women than in men [2,3]. COPD patients with airway
hyper-responsiveness have an elevated risk of experiencing
an accelerated decline in FEV1 [4,5].
Due to the structural changes and destruction that occur
in the lung parenchyma in COPD patients, there is an in-
crease in small airway resistance and a loss of lung elastic
recoil, leading to a decline in the FEV1. It is assumed that
these changes can lead to airflow obstruction [6,7];Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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changes [8]. Additionally, the correlation between FEV1
and dyspnea in COPD subjects is weak; a better correlation
has been found between the forced inspiratory volume in
one second (FIV1) and dyspnea [9].
Nevertheless, using FEV1 to evaluate the response to a
bronchial challenge is widely accepted [10]. This accept-
ance is probably due to the simplicity of the measure-
ment and its well-known reproducibility. Unlike FEV1
changes, the effects of inhaled histamine in COPD
patients and the associated changes in inspiratory lung
function parameters (ILPs) in stable, mild to moderate
COPD patients are relatively unknown.
Dynamic airway compression during forced expiratory
maneuvers can mask the effects of intervention with
bronchodilators (e.g., salbutamol) or bronchoconstrictors
(e.g., histamine). Because dynamic compression does not
occur during inspiratory maneuvers, we reasoned that
there should be more observable change in the ILPs
than in the FEV1 after administering the bronchocon-
strictor histamine. Therefore, we hypothesized that the
ILPs may be more sensitive to histamine bronchocon-
striction than the FEV1 and may correlate more closely
with dyspnea.
The objectives of the present study included the following:
to investigate the effects of inhaled histamine on the FIV1,
inspiratory capacity (IC), forced inspiratory flow at 50% of
the vital capacity (FIF50) and peak inspiratory flow (PIF), to
study the changes in these inspiratory parameters at the time
that the provocative dose produces a ≥20% decrease in the
FEV1 and to investigate the correlation between the changes
in these lung function parameters and the degree of dyspnea
change, as measured by a visual analogue scale (VAS), when
the bronchial challenge test is considered positive.
Methods
Study design
Forty patients (including 12 women) with stable COPD
were recruited from the outpatient clinic of the pulmonary
department of the Canisius Wilhelmina Hospital in Nij-
megen. The subjects had COPD that was classified as mild
to moderate (at GOLD (Global Initiative for Chronic Ob-
structive Lung Disease) stage I or II based on postbroncho-
dilator FEV1 values [11,12]. The patients met the inclusion
criteria if they had stable COPD, were between the ages of
40 and 80 years, were current or former smokers with at
least a 10 pack-year history and did not demonstrate revers-
ibility after using short-acting bronchodilators. Although re-
versibility can be defined as an increase in FEV1 that is
both greater than 200 ml and 12% above the pre-broncho-
dilator FEV1 value, our patients were required to have his-
torical records demonstrating less than 10% standardized
reversibility (as a percentage of predicted FEV1) to short-
acting bronchodilators [13,14].All of the included patients were in a stable disease state.
Five patients were being treated with short-acting beta-2-
agonists, 4 patients with short-acting anticholinergics, 24
patients with long-acting beta-2-agonists, 19 patients with
long-acting anticholinergics, 16 patients with inhaled corti-
costeroids and 2 patients with oral theophylline. No patients
were using oral corticosteroids. The patients visited the spir-
ometry laboratory in the morning after having refrained from
using inhaled corticosteroids for at least one week, from
using short-acting inhaled bronchodilators for at least 6
hours, from using long-term beta-2-agonist bronchodilators
for 12 hours and from using tiotropium or theophylline for
at least 24 hours. No patients received antihistamines during
the week prior to the study. The patients were defined as
clinically stable if they had not had COPD exacerbations or
changes in their COPD medications over the previous
8 weeks, had not used oral corticosteroids for a period of
two months prior to the study and had not used antibiotics
within the previous month. The exclusion criteria included
an FEV1< 50% of the predicted value, oxygen therapy, being
unable to complete the questionnaires and the presence of
allergic rhinitis, asthma, heart disease, neuromuscular disor-
ders and any known form of pulmonary malignancy.
The Medical Ethics Committee of Arnhem-Nijmegen
in the Netherlands gave permission for this study, and
all of the patients gave their written informed consent
prior to study participation.
The histamine provocation test
The histamine inhalation tests were performed according
to the ERS standards [1]. The histamine solutions were
stored at 4 degrees Celsius and were administered at room
temperature. Six doses of histamine-acetyl-beta-methyl-
choline-chloride (0.04 mg, 0.09 mg, 0.18 mg, 0.29 mg,
0.71 mg and 1.30 mg, yielding a cumulative dose ranging
from 0.04 to 2.60 mg) in normal saline were inhaled by
tidal breathing for 1 min at 5-min intervals using a Koko
DigiDoser dosimeter (PPS Research, Louisville, CO, USA).
BHR was defined as a PD20< 2.60 mg (8.48 μmol). The
PD20 value is the provocative dose of inhaled histamine
that produces a decrease of 20% or more in the FEV1.
The baseline standard spirometry tests were performed
first. Five FIV1 maneuvers were performed according to the
procedures reported in our previous study, in which the
subjects were asked to exhale slowly until reaching the re-
sidual volume level and to subsequently perform a forced,
deep inspiration until reaching the total lung capacity
(TLC) level [15]. The best values for the FIV1, IC, FIF50 and
PIF were obtained from these data. Subsequently, three
FEV1 flow volume curves were obtained according to the
ERS standards, and the best FEV1 was recorded. The IC
was measured immediately before each forced inhalation
using the method described by Hadcroft and Calverly [16].
If the vital capacity (VC) was reached before the FIV1
Table 1 The patient characteristics and baseline lung
function parameters for the 39 subjects in this study
Male/Female ratio, numbers (percentage) 12/27 (31%/69%)
Age, years 66 ± 7
Smoker, (ex-/current)$ 13/26 (33%/67%)
GOLD stage 1 patients, number 10
GOLD stage 2 patients, number 29
FEV1, L/s (pre-bronchoconstriction) 1.89 ± 0.46
FVC, L (pre-bronchoconstriction) 3.11 ± 0.72
FEV1/FVC (%, pre-bronchoconstriction) 61.1 ± 8.1
FEV1 (% predicted) 67.0 ± 11.1
FEV1, L/s (post-bronchoconstriction) 1.67 ± 0.49
FVC, L (post-bronchoconstriction) 2.83 ± 0.73
FIV1, L/s 2.92 ± 0.75
IC, L 2.32 ± 0.53
FIF50, L/s 4.97 ± 1.40
PIF, L/s 5.40 ± 1.48
PD20, mg 0.13 (0.04 to >2.60
#)
Definition of abbreviations:
FEV1 = forced expiratory volume (L) in 1 second.
FIV1 = forced inspiratory volume (L) in 1 second.
IC = inspiratory capacity (L).
FIF50 = forced inspiratory flow at 50% of the vital capacity (L/s).
PIF = peak inspiratory flow (L/s).
PD20 = dose of histamine causing ≥ 20% decrease in FEV1 from the baseline
value.
GOLD = Global Initiative for Chronic Obstructive Lung Disease.
Values are given as the mean ± SD, except for PD20, which is given as the
median (range).
$ All of the patients had smoked at least 10 pack-years.
# The highest histamine dose tested was 2.60 mg.
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FIV1 =VC. The largest FVC and FEV1 values were recorded.
The reference values from the European Community for
Steel and Coal were used for the predicted FEV1 and forced
vital capacity (FVC) values [17]. In the current study, the
subjects who were exhausted and whose FIV1 and FEV1
values decreased by less than 10% from the baseline values
were restricted to three forced inspiratory and three forced
expiratory maneuvers. For the rest of the subjects, five forced
inspiratory and three forced expiratory maneuvers were per-
formed. After a pre-test with a saline aerosol solution, the
challenges with sequential inhalations of the histamine aero-
sol began. A 1-min rest interval was provided between each
dose of histamine. Afterwards, the above-mentioned stand-
ard lung function tests were performed. The challenge was
terminated when there was an FEV1 decline of at least 20%
or after the maximum histamine dose was administered.
The patients with more than a 20% decrease in the FEV1
value after histamine administration were treated with four
puffs of fenoterol 100 mcg/ipratropium 20 mcg to aid their
recovery. For each patient, the PD20 value of the inhaled his-
tamine was estimated by log-linear interpolation [18]. We
used the one-hour repeatability of these lung function para-
meters (the random variation expressed as the coefficients of
repeatability (CR)) to compare the effects of the inhaled his-
tamine on the ILPs and FEV1 [19].
Dyspnea score
The patients rated changes in dyspnea post-histamine ad-
ministration using a VAS scale. The VAS scale is a 10-cm-
long horizontal line that ranges from −5 to + 5 cm. VAS=
−5 indicates significantly improved dyspnea, VAS= 0 indi-
cates no change, and VAS= +5 indicates significantly wor-
sened dyspnea. Prior to the test, all subjects were instructed
on how to use the VAS scale.
Statistical analysis
The one-sample t-test was used to compare the mean
changes in lung function parameters from the baseline to
the changes following different histamine dose steps. A
repeated measures analysis of variance, ANOVA, was used
to compare the mean changes in the various lung function
parameters at the different dose steps. Pairwise compari-
sons of the lung function changes were made using the
paired t-test. Spearman’s correlation coefficients (rS) were
calculated. Receiver Operating Characteristic (ROC) curves
was constructed to investigate the predictive value of the
percentage change from baseline in the various ILPs in re-
gard to reaching the PD20 endpoint. The areas under the
curve (AUC) were calculated, and an AUC> 0.80 was con-
sidered to denote good predictive value. The analyses were
performed using SPSS version 15.1 for Windows. A differ-
ence with a two-sided p-value< 0.05 was considered to be
significant. Among the 39 included patients, we expectedthat at least 36 would reach the PD20 endpoint. With 36
patients, a correlation of 0.45 or greater between the FEV1
or ILP changes from baseline and the VAS could be
detected at an alpha of 0.05 with a power of at least 80%.Results
Patient characteristics
The baseline lung function values and patient characteristics
are listed in Table 1. Only one of the forty subjects was
excluded from the study. This subject developed persistent,
severe dyspnea and had an FEV1 decrease of almost 19%
after the first dose of histamine. One of the subjects stopped
participating after the fourth dose; therefore, only seven
patients participated up to dose step 5. Furthermore, two
patients did not exhibit a significant response, despite
being administered the highest dose.Changes in lung function parameters after each dose of
histamine during the histamine provocative test
The effect of histamine on the various ILPs is shown in
Table 2. Following the last administered dose of
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positive provocation response. Figure 1 presents the
mean changes from the baseline values observed at the
various dose steps. All of the mean changes up to the
sixth dose step were significantly less than zero, with the
exception of the FIF50 at the fourth dose step. The
ANOVA indicated significant differences between the
various lung function changes at dose steps 1, 2 and 3
(all p< 0.006). The FEV1 generally displayed the largest
decrease at these dose steps, and the FIF50 displayed the
smallest. At dose steps 1, 2 and 3, the mean FEV1 de-
crease was significantly greater than the corresponding
FIF50 and PIF changes. No significant differences were
found between the FEV1 changes and the changes in the
FIV1 or IC. Possibly due to the small number of
remaining patients, no significant differences were found
among the measured parameters at dose steps 4, 5 or 6.Changes in lung function parameters after inhaling
histamine when PD20 is reached
The PD20 endpoint was reached and the one-hour CR
was investigated in 36 of the 39 patients. We defined a
responder as a subject who demonstrated a change in a
parameter value greater than the following CRs: 12% for
FEV1, 14% for FIV1, 19% for IC, 21% for FIF50 and 18%
for PIF [19]. The results are summarized in Table 3. At
PD20, more FEV1 responders were found than ILP
responders. FIV1 and the IC were more sensitive than
the flow parameters (FIF50 and PIF). To investigate
which ILP was the best predictor of the occurrence of
the PD20 endpoint, ROC curves were constructed for
each ILP. Figure 2 demonstrates that the changes fromTable 2 The percentage changes from the baseline lung func
six histamine doses
Mean value
dose step 1 dose step 2 dose step 3
FEV1 -12.0 ± 7.8 -15.2 ± 10.1 -17.4 ± 9.1
FIV1 -10.4 ± 8.4 -14.1 ± 9.2 -14.6 ± 9.2
IC -12.4 ± 10.5 -13.1 ± 13.6 -11.7 ± 14
FIF50 -5.2 ± 11.3 -6.0 ± 9.1 -8.1 ± 12.4
PIF -7.3 ± 9.7 -8.7 ± 8.2 -11.6 ± 10
VAS 0.3 ± 1.0 0.7 ± 1.1 1.3 ± 0.9
N1 39 32 20
N2 7 12 11
Definition of abbreviations:
FEV1 = forced expiratory volume in 1 second.
FIV1 = forced inspiratory volume in 1 second.
IC = inspiratory capacity (L).
FIF50 = forced inspiratory flow at 50% of the vital capacity (L/s).
PIF = peak inspiratory flow (L/s).
VAS = VAS score for the change of dyspnea after each histamine dose.
N1 = number of subjects tested at the given histamine dose.
N2 = number of subjects with a FEV1 decrease from baseline of ≥ 20% at the giventhe baseline FIV1 and IC values had the best predictive
values (both AUCs were equal to 0.78). The predictive
values of the FIF50 and PIF were somewhat lower, with
AUCs of 0.71 and 0.67, respectively.
The relationships between the percentage changes
from the initial FEV1 values and the changes in the ILPs
after the PD20 endpoint dose was reached are presented
in Table 4. The mean percentage changes for all of the
ILPs differed significantly from the corresponding
changes in FEV1 (p< 0.04 for all parameters). In
addition, all of the mean changes in the ILPs differed
significantly from each other, with the exception of the
changes in FIV1 versus the changes in IC (p = 0.75). Only
the changes in FIV1 correlated significantly with the
changes in FEV1. After reaching the PD20 endpoint, 8 of
the 36 subjects had a decrease of more than 20% in their
FIF50 and PIF values.Relationship between changes in lung function parameters
and changes in dyspnea measured with the VAS
The mean VAS score gradually increased with increasing
histamine doses, indicating an increase in dyspnea from
dose step 1 to dose step 5 (p< 0.001). No significant cor-
relations were found between the changes in the lung
function parameters and the VAS score at the dose where
the FEV1 had fallen by 20% or more from the baseline
(Table 5).Discussion
The results of the present study demonstrate that the ILPs
and FEV1 are sensitive to broncho-obstructive challenges.
After each dose of histamine, there was a statisticallytion parameters and VAS dyspnea scores after each of the
s (± SD)
dose step 4 dose step 5 dose step 6
-14.4 ± 6.8 -18.8 ± 5.9 -20.7 ± 4.5
-17.6 ± 7.6 -19.6 ±7.4 -23.7 ± 15.3
-13.3 ± 8.2 -16.3 ± 8.7 -20.9 ± 14.0
-4.2 ± 8.9 -10.9 ± 8.2 -24.0 ± 13.3
-12.7 ± 8.1 -14.7 ± 7.7 -27.9 ± 16.9
1.3 ± 1.0 1.6 ± 1.2 1.2 ± 1.6
9 7 4
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Figure 1 The changes from the baseline values (± SEM) of the FIF50 (open squares), PIF (solid squares), IC (open circles), FIV1 (solid
circles) and FEV1 (triangles) after each dose of histamine;n = number of subjects tested at each histamine dose step.
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decrease being observed in the FEV1. The declines among
the ILPs differed. The changes in the IC and FIV1 were lar-
ger than the FIF50 and PIF responses. Until now, no studiesTable 3 The ILP changes upon reaching the PD20
endpoint in 36 patients, stratified by the coefficient of
repeatability of the various lung function parameters
response criterion non-responder/responder
(at PD20 endpoint FEV1)
FEV1 response >12%* 0 vs. 36
(0% vs. 100%)
FIV1 response >14%* 10 vs. 26
(28% vs. 72%)
IC response> 19%* 14 vs. 22
(39% vs. 61%)
FIF50 response >21%* 28 vs. 8
(78% vs. 22%)
PIF response>18%* 24 vs. 12
(67% vs. 33%)
Definition of abbreviations:
* = one-hour coefficient of repeatability of the particular lung function
parameter.
FEV1 = forced expiratory volume in 1 second.
FIV1 = forced inspiratory volume in 1 second.
IC = inspiratory capacity (L).
FIF50 = forced inspiratory flow at 50% of the vital capacity (L/s).
PIF = peak inspiratory flow (L/s).have examined the effects of histamine on the ILPs of sub-
jects with mild to moderate forms of COPD. A greater
number of FEV1 responders than ILP responders were
found. Furthermore, the nadir was more pronounced in the
FEV1 group than in the ILP group. Because the FEV1
changes were more sensitive to inhaled histamines com-
pared to the ILP changes, we rejected our hypothesis that
the ILPs might be more sensitive tools for detecting a
bronchoconstrictive response than the FEV1. This finding
may have been due to the small number of patients who
participated in this study, but this result is consistent with a
previous finding that FEV1 is a more sensitive parameter
for detecting a bronchodilator response than the ILPs [20].
Of all of the ILPs, only changes in FIV1 were found to
have a significant (but moderate) correlation with the corre-
sponding changes in FEV1 (rS = 0.47, p = 0.004) at the PD20
endpoint. Only 8 of the 36 subjects had a decrease of more
than 20% in FIF50 and PIF. Additionally, the FIV1 and IC
were more sensitive than the FIF50 and PIF. The FIV1 and
IC changes from baseline again had the best predictive
value for determining the patients who would reach the
endpoint. There are currently no reports in the literature
that support this finding. An overview of our PD20 endpoint
data indicates that only two of the included subjects did not
have a positive challenge test at the final dose. The majority
of the population (30 subjects or approximately 77%)
1 - Specificity
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Figure 2 The ROC curves for predicting the occurrence of an FEV1 decrease ≥20% using the changes from the baseline values (%) of
the FIV1, IC, FIF50 and PIF. The areas under the curve are 0.78, 0.78, 0.71 and 0.66. The dotted line represents a test with no predictive value.
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histamine doses. In a study by Kanner et al., the prevalence
of BHR in subjects with mild COPD varied between 25-
48%; furthermore, the prevalence of BHR was reported to
be approximately 66% in mild or early COPD subjects in
the Lung Health Study [21,22]. However, a study by Taube
et al. of nine subjects with stable, mild to severe COPD
found a positive challenge test for all nine subjects afterTable 4 The mean percentage changes from the initial
FEV1 and ILP values in 36 subjects after inhaling
histamine at the endpoint dose step
(FEV1 decrease ≥20%)
mean percentage changes
from initial values ± SD
correlation (rS) with
changes in FEV1
FEV1 -24.9 ± 3.7 (n.t.) -
FIV1 -20.1 ± 9.3 (p< 0.001) 0.47(p = 0.004)
IC -20.6 ± 12.5 (p< 0.001) 0.22 (p = 0.206)
FIF50 -12.6 ± 11.1 (p< 0.001) 0.17 (p = 0.322)
PIF -14.6 ± 11.2 (p< 0.001) 0.24 (p = 0.161)
Definition of abbreviations:
FEV1 = forced expiratory volume (L) in 1 second.
FIV1 = forced inspiratory volume (L) in 1 second.
IC = inspiratory capacity (L).
FIF50 = forced inspiratory flow at 50% of the vital capacity (L/s).
PIF = peak inspiratory flow (L/s).
n.t. = not tested (less than -20% by design).administering inhaled histamine [23]. Asthma patients were
excluded from our study. We made an active effort to ex-
clude patients with diagnosed or possible undiagnosed
asthma with well-defined inclusion and exclusion criteria.
The high histamine sensitivity of our study population
may have been due to several reasons. First, 13 subjects
(33%) were current smokers, and 26 subjects (67%) were
former smokers. In smokers with mild COPD, the pres-
ence of many mast cells in the COPD airways may lead to
BHR [24]. Second, some of these subjects had gastro-Table 5 The Spearman correlations of the VAS results
with the changes (%) from the initial lung function
values in 36 subjects after inhaling histamine at the
endpoint dose step (FEV1 decrease ≥20%)
Δ FEV1-
VAS
ΔFIV1-
VAS ΔIC-VAS
Δ FIF50-
VAS ΔPIF-VAS
rS 0.12 -0.10 0.08 -0.33 -0.30
p-value 0.482 0.554 0.655 0.053 0.079
Definition of abbreviations:
FEV1 = forced expiratory volume in 1 second.
FIV1 = forced inspiratory volume in 1 second.
IC = inspiratory capacity (L).
FIF50 = forced inspiratory flow at 50% of the vital capacity (L/s).
PIF = peak inspiratory flow (L/s).
Δ = changes in initial values of lung function parameters when reaching the
PD20 endpoint.
A higher VAS score denotes a higher degree of dyspnea.
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some of the subjects had used inhaled corticosteroids
(ICS). Withdrawal of ICS, which are known to reduce the
maximal degree of airway narrowing, prior to entering the
study may have led to an increased sensitivity to broncho-
constriction. While ICS have been proven to be important
in reducing BHR in asthmatic subjects, they have not been
found to be particularly effective in subjects with COPD
[26]. Jarad et al. suggested that even in subjects with
COPD, the abrupt withdrawal of inhaled corticosteroids
should be instituted carefully [27].
No statistically significant correlations were found be-
tween the lung function parameters and the degree of dys-
pnea as measured by the VAS. These findings are
inconsistent with those of Taube et al., who found a more
significant correlation between the relative FIV1 changes
(r = 0.730, p< 0.001) and VAS than between the FEV1
changes (r = 0.389, p< 0.01) and VAS after administering
the bronchodilator salbutamol in patients with stable
COPD [28]. The finding that FEV1 and ILPs do not correl-
ate with dyspnea is consistent with the results of our previ-
ously mentioned study of 85 stable COPD patients, in
which we found no significant VAS changes after using
short-term bronchodilators. Therefore, we also rejected
our hypothesis that ILPs correlated more strongly with
dyspnea following a histamine challenge. This difference
may also have been due to the small number of patients
who participated in our study and to our patient popula-
tion having mild to moderate COPD rather than severe
COPD, as in the study by Taube. Another possible explan-
ation for the poor correlation between the FEV1 and VAS
in our study is that most of the subjects had stable COPD
for at least two months and were probably low perceivers
[29]. The most common lung function variables used to
evaluate the degree of correlation with dyspnea in COPD
subjects are the PEF and FEV1 [30]. There are no other
available studies of the sensitivity of dyspnea scores in
COPD subjects that have investigated the perception of
dyspnea after administering inhaled histamine.Conclusions
We found that the FEV1 appeared to be more sensitive than
the ILPs to increasing doses of inhaled histamine in subjects
with stable, mild to moderate COPD. Although there was a
decline in the FEV1 and in all of the ILPs, the largest de-
crease observed was in the FEV1. In vition, a greater num-
ber of responders were found when we focused on the
FEV1 rather than on the ILPs. The FIF50 and the PIF
appeared to be the least sensitive measures. Of the ILPs,
the FIV1 and IC were the best predictors of which patients
would reach the PD20 endpoint. No statistically significant
correlations were found between the lung function para-
meters and the degree of dyspnea as measured by the VAS.Abbreviations
BHR: Bronchial hyper-responsiveness; FEV1: Forced expiratory volume in 1 s;
FIV1: Forced inspiratory volume in 1 s; IC: Inspiratory capacity (L);
FIF50: Forced inspiratory flow at 50% of the vital capacity (L/s); PIF: Peak
inspiratory flow (L/s); PD20: Dose of histamine causing≥ 20% decrease in FEV1
from the baseline value; VAS: Visual analogue scale; GOLD: Global initiative for
chronic obstructive lung disease; ILPs: Inspiratory lung function parameters.
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